Raleigh Capital Management »

Janux Therapeutics shares owned by Raleigh Capital Management

Quarter-by-quarter ownership of Janux Therapeutics (JANX) shares owned by Raleigh Capital Management from 13F filings

Historical chart of Raleigh Capital Management investment in Janux Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Janux Therapeutics held by Raleigh Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Janux Therapeutics by Raleigh Capital Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $2.9k 270 10.73

More positions owned by Raleigh Capital Management

Ishares Tr Core S&p500 Etf (IVV)
Spdr S&p 500 Etf Tr Tr Unit (SPY)
Ssga Active Tr Spdr Ssga Fxd (FISR)
Ssga Active Tr Spdr Ssga Us Sct (XLSR)
Invesco Qqq Tr Unit Ser 1 (QQQ)
Philip Morris International (PM)
Verizon Communications (VZ)
Spdr Index Shs Fds Portfolio Emg Mk (SPEM)
Totalenergies Se Sponsored Ads (TTE)
Duke Energy Corp Com New (DUK)
Apple (AAPL)
Microsoft Corporation (MSFT)
Southern Company (SO)
Spdr Ser Tr Portfolio Agrgte (SPAB)
Abbvie (ABBV)

View all positions for Raleigh Capital Management

Top funds holding Janux Therapeutics

RA Capital Management
BVF
OrbiMed Advisors
Citadel Advisors
Henderson Group
Vanguard Group
Samsara BioCapital
Alyeska Investment Group
Millennium Management
Squarepoint Ops
HPM Partners
Zacks Investment Management
Capstone Investment Advisors
DekaBank Deutsche Girozentrale
Bank of New York Mellon

View all funds holding Janux Therapeutics